ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), PMN310, and additional studies that further characterize a computationally-derived AD vaccine at AAIC 2023.
What To Know: PMN310 was able to target toxic amyloid-beta oligomers more selectively than other amyloid-beta-directed antibodies which were generated using synthetic oligomers, according to new findings.
"We are excited about the new data presented at the AAIC conference on mechanisms and monitoring of Alzheimer's disease and emerging treatment options which we believe may improve the lives of patients and their families," said Gail Farfel, CEO of ProMIS Neurosciences.
"The increasingly recognized benefit of targeting oligomers of Aβ underscores the potential advantage of our PMN310 antibody and AβO vaccine candidates.
In May 2023, ProMIS received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PMN310 for the treatment of AD.
Related Link: Eli Lilly's Alzheimer's Drug Candidate Slows Progression By 60% In Mildly Impaired Patients
PMN Price Action: Shares of PMN were up 113.5% at $6.00 at the time of publication, according to Benzinga Pro.
Image by Michal Jarmoluk from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
